CS 706 [R109339], a novel COX-2-selective inhibitor, is associated with less GI toxicity than naproxen

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1584, 2007-01, pp. : 12-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical pharmacology of etoricoxib: a novel selectiveCOX2 inhibitor

By Patrignani Paola   Capone Marta L   Tacconelli Stefania  

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 2, 2003-02 ,pp. : 265-284

Informa Healthcare

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Reports of COX-2 inhibitor-associated arrhythmias in NZ

By  

Reactions Weekly, Vol. 1, Iss. 1076, 2005-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Clinical Pharmacology of Novel Selective COX-2 Inhibitors

By  

Current Pharmaceutical Design, Vol. 10, Iss. 6, 2004-02 ,pp. : 589-601

Bentham Science Publishers

Access to resources Recommend Favorite

Etodolac (Lodine ® ): Profile of an established selective COX-2 inhibitor

By Jones Richard A.  

Inflammopharmacology, Vol. 9, Iss. 1-2, 2001-05 ,pp. : 63-70

VSP

Access to resources Recommend Favorite